{"id":271783,"date":"2025-11-04T22:35:12","date_gmt":"2025-11-04T22:35:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/271783\/"},"modified":"2025-11-04T22:35:12","modified_gmt":"2025-11-04T22:35:12","slug":"tenaya-therapeutics-announces-aha-late-breaking-tn-201-data","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/271783\/","title":{"rendered":"Tenaya Therapeutics Announces AHA Late-Breaking TN-201 Data"},"content":{"rendered":"


\n
\n
\n
\n
\n
\n
\n <\/p>\n

Tenaya Therapeutics (NASDAQ: TNYA) announced two late-breaking oral presentations at the American Heart Association Scientific Sessions 2025 on November 8\u20139, 2025 highlighting new clinical and preclinical data.<\/p>\n

Key items: interim safety and efficacy results from dose cohorts 1 and 2 of the MyPEAK-1 Phase 1b\/2a study of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy will be presented on Nov 8, 2025, 10:25\u201310:35 am CT by Milind Y Desai, M.D., MBA. A separate late-breaking oral presentation of a cellular reprogramming gene therapy showing significant and durable improvement in cardiac function in a pig ischemic heart failure model will be presented on Nov 9, 2025, 8:00\u20138:10 am CT by Kathy Ivey.<\/p>\n

Tenaya will host a webcast and conference call on Nov 10, 2025 at 8:00 am ET to discuss MyPEAK-1 data; presentations will be posted on the company website after each session.<\/p>\n

Tenaya Therapeutics (NASDAQ: TNYA) ha annunciato due presentazioni orali tardive ai American Heart Association Scientific Sessions 2025 il 8-9 novembre 2025, evidenziando nuovi dati clinici e preclinici.<\/p>\n

Elementi chiave: risultati intermedi di sicurezza ed efficacia dai coorti di dosaggio 1 e 2 dello studio MyPEAK-1 Phase 1b\/2a di TN-201 per la cardiomiopatia ipertrofica associata a MYBPC3 saranno presentati il 8 novembre 2025, ore 10:25\u201310:35 CT da Milind Y Desai, M.D., MBA. Una presentazione orale tardiva separata di una terapia genica di riprogrammazione cellulare che mostra un miglioramento significativo e duraturo della funzione cardiaca in un modello di cancro ischemico su maiale sar\u00e0 presentata il 9 novembre 2025, ore 8:00\u20138:10 CT da Kathy Ivey.<\/p>\n

Tenaya ospiter\u00e0 un webcast e conference call il 10 novembre 2025 alle ore 8:00 ET per discutere i dati MyPEAK-1; le presentazioni saranno pubblicate sul sito web dell’azienda dopo ogni sessione.<\/p>\n

Tenaya Therapeutics (NASDAQ: TNYA) anunci\u00f3 dos presentaciones orales de \u00faltima hora en las Sesiones Cient\u00edficas de la Asociaci\u00f3n Americana del Coraz\u00f3n 2025 los d\u00edas 8-9 de noviembre de 2025, destacando nuevos datos cl\u00ednicos y precl\u00ednicos.<\/p>\n

Art\u00edculos clave: resultados interinos de seguridad y eficacia de las cohortes de dosis 1 y 2 del estudio MyPEAK-1 fase 1b\/2a de TN-201 para la miocardiopat\u00eda hipertr\u00f3fica asociada a MYBPC3 se presentar\u00e1n el 8 de noviembre de 2025, 10:25\u201310:35 am CT por Milind Y Desai, M.D., MBA. Una presentaci\u00f3n oral tard\u00eda separada de una terapia g\u00e9nica de reprogramaci\u00f3n celular que muestra una mejora significativa y duradera de la funci\u00f3n card\u00edaca en un modelo de fallo card\u00edaco isqu\u00e9mico en cerdos se presentar\u00e1 el 9 de noviembre de 2025, 8:00\u20138:10 am CT por Kathy Ivey.<\/p>\n

Tenaya organizar\u00e1 una transmisi\u00f3n en directo y conferencia telef\u00f3nica el 10 de noviembre de 2025 a las 8:00 am ET para discutir los datos MyPEAK-1; las presentaciones se publicar\u00e1n en el sitio web de la empresa despu\u00e9s de cada sesi\u00f3n.<\/p>\n

\ud14c\ub098\uc57c \ud14c\ub77c\ud4e8\ud2f1\uc2a4(Tenaya Therapeutics, NASDAQ: TNYA)\uac00 2025\ub144 11\uc6d4 8-9\uc77c \ubbf8\uad6d \uc2ec\uc7a5\ud611\ud68c \uacfc\ud559 \uc138\uc158\uc5d0\uc11c \uc0c8\ub85c\uc6b4 \uc784\uc0c1 \ubc0f \uc804\uc784\uc0c1 \ub370\uc774\ud130\ub97c \uac15\uc870\ud558\ub294 \ub2a6\uc740 \ubc1c\ud45c \ub450 \ud3b8\uc744 \ubc1c\ud45c\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n

\ud575\uc2ec \ub0b4\uc6a9: \ucd08\uae30 \uc548\uc804\uc131 \ubc0f \ud6a8\ub2a5 \uacb0\uacfc\ub294 MYBPC3 \uad00\ub828 \ube44\ub300\uc131 \uc2ec\uadfc\uc99d\uc758 TN-201\uc758 1\uc0c1\/2a 1\u00b72 \ucf54\ud638\ud2b8\uc758 \uc6a9\ub7c9 \ucf54\ud638\ud2b8\uc5d0\uc11c \ubc1c\ud45c\ub420 \uc608\uc815\uc774\uba70, \ubc1c\ud45c\uc790\ub294 Milind Y Desai, M.D., MBA\uc774\uba70 \ubc1c\ud45c\uc77c\uc740 2025\ub144 11\uc6d4 8\uc77c, 10:25\u201310:35 am CT\uc785\ub2c8\ub2e4. \ub610 \ub2e4\ub978 \uc138\ud3ec \uc7ac\ud504\ub85c\uadf8\ub798\ubc0d \uc720\uc804\uc790 \uce58\ub8cc\uac00 \ub3fc\uc9c0 \ud5c8\ud608\uc131 \uc2ec\ubd80\uc804 \ubaa8\ub378\uc5d0\uc11c \uc2ec\uc7a5 \uae30\ub2a5\uc758 \uc720\uc758\ubbf8\ud558\uace0 \uc9c0\uc18d\uc801\uc778 \uac1c\uc120\uc744 \ubcf4\uc600\ub2e4\ub294 \ubcc4\ub3c4\uc758 \ub2a6\uc740 \ubc1c\ud45c\uac00 2025\ub144 11\uc6d4 9\uc77c, 8:00\u20138:10 am CT\uc5d0 Kathy Ivey\uc5d0 \uc758\ud574 \ubc1c\ud45c\ub429\ub2c8\ub2e4.<\/p>\n

\ud14c\ub098\uc57c\ub294 \uc6f9\uce90\uc2a4\ud2b8 \ubc0f \ucee8\ud37c\ub7f0\uc2a4 \ucf5c\uc744 2025\ub144 11\uc6d4 10\uc77c \uc624\uc804 8:00 ET\uc5d0 \uc8fc\ucd5c\ud558\uc5ec MyPEAK-1 \ub370\uc774\ud130\ub97c \ub17c\uc758\ud560 \uc608\uc815\uc774\uba70, \uac01 \uc138\uc158 \ud6c4 \ud68c\uc0ac \uc6f9\uc0ac\uc774\ud2b8\uc5d0 \ubc1c\ud45c\uac00 \uac8c\uc2dc\ub429\ub2c8\ub2e4.<\/p>\n

Tenaya Therapeutics (NASDAQ: TNYA) a annonc\u00e9 deux pr\u00e9sentations orales de derni\u00e8re minute lors des Sessions scientifiques de l\u2019American Heart Association 2025 les 8 et 9 novembre 2025, mettant en \u00e9vidence de nouvelles donn\u00e9es cliniques et pr\u00e9cliniques.<\/p>\n

Points cl\u00e9s : r\u00e9sultats pr\u00e9liminaires de s\u00e9curit\u00e9 et d\u2019efficacit\u00e9 des cohorts de dose 1 et 2 de l\u2019\u00e9tude MyPEAK-1 Phase 1b\/2a de TN-201 pour l\u2019hypertrophie cardiaque associ\u00e9e \u00e0 MYBPC3 seront pr\u00e9sent\u00e9s le 8 novembre 2025, 10:25\u201310:35 am CT par Milind Y Desai, M.D., MBA. Une pr\u00e9sentation orale tardive distincte d\u2019une th\u00e9rapie g\u00e9nique de reprogrammation cellulaire montrant une am\u00e9lioration significative et durable de la fonction cardiaque dans un mod\u00e8le d\u2019insuffisance cardiaque isch\u00e9mique chez le porc sera pr\u00e9sent\u00e9e le 9 novembre 2025, 8:00\u20138:10 am CT par Kathy Ivey.<\/p>\n

Tenaya organisera un webcast et conf\u00e9rence t\u00e9l\u00e9phonique le 10 novembre 2025 \u00e0 8:00 am ET pour discuter des donn\u00e9es MyPEAK-1 ; les pr\u00e9sentations seront publi\u00e9es sur le site Web de l\u2019entreprise apr\u00e8s chaque session.<\/p>\n

Tenaya Therapeutics (NASDAQ: TNYA) k\u00fcndigte zwei mit Verz\u00f6gerung vorgetragene Vortr\u00e4ge bei den Scientific Sessions der American Heart Association 2025 am 8.\u20139. November 2025 an und hob neue klinische und pr\u00e4klinische Daten hervor.<\/p>\n

Wichtige Punkte: vorl\u00e4ufige Sicherheits- und Wirksamkeitsdaten aus den Dosiskohorten 1 und 2 der MyPEAK-1-Phase-1b\/2a-Studie von TN-201 bei MYBPC3-assoziierter hypertropher Cardiomyopathie werden am 8. November 2025, 10:25\u201310:35 Uhr CT von Milind Y Desai, M.D., MBA, vorgestellt. Eine separate sp\u00e4te m\u00fcndliche Pr\u00e4sentation einer zellul\u00e4ren Reprogrammierungs-Gentherapie, die eine signifikante und dauerhafte Verbesserung der Herzfunktion in einem Schweinemodell iskhemischer Herzinsuffizienz zeigt, wird am 9. November 2025, 8:00\u20138:10 Uhr CT von Kathy Ivey pr\u00e4sentiert.<\/p>\n

Tenaya wird am 10. November 2025 um 8:00 Uhr ET eine Webcast und Conference Call veranstalten, um die MyPEAK-1-Daten zu diskutieren; Pr\u00e4sentationen werden nach jeder Sitzung auf der Website des Unternehmens ver\u00f6ffentlicht.<\/p>\n

Tenaya Therapeutics (NASDAQ: TNYA) \u0623\u0639\u0644\u0646\u062a \u0639\u0646 \u062c\u0644\u0633\u062a\u064a\u0646 \u0634\u0641\u0648\u064a\u062a\u064a\u0646 \u0645\u062a\u0623\u062e\u0631\u062a\u064a\u0646 \u0641\u064a \u062c\u0644\u0633\u0627\u062a \u0627\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0644\u0642\u0644\u0628 2025 \u0641\u064a 8-9 \u0646\u0648\u0641\u0645\u0628\u0631 2025 \u0645\u0639 \u0625\u0628\u0631\u0627\u0632 \u0628\u064a\u0627\u0646\u0627\u062a \u062c\u062f\u064a\u062f\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0645\u0627 \u0642\u0628\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629.<\/p>\n

\u0646\u0642\u0627\u0637 \u0631\u0626\u064a\u0633\u064a\u0629: \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0648\u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0645\u0624\u0642\u062a\u0629 \u0645\u0646 \u0639\u064a\u0651\u0646\u0627\u062a \u0627\u0644\u062c\u0631\u0639\u0627\u062a 1 \u0648 2 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 MyPEAK-1 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 1b\/2a \u0644\u0640 TN-201 \u0644\u0627\u0639\u062a\u0644\u0627\u0644 \u0639\u0636\u0644\u0629 \u0627\u0644\u0642\u0644\u0628 \u0627\u0644\u062a\u0636\u062e\u0645\u064a \u0627\u0644\u0645\u0631\u062a\u0628\u0637 \u0628\u0640 MYBPC3 \u0633\u062a\u064f\u0639\u0631\u0636 \u0641\u064a 8 \u0646\u0648\u0641\u0645\u0628\u0631 2025\u060c \u0627\u0644\u0633\u0627\u0639\u0629 10:25\u201310:35 \u0635 \u0628\u062a\u0648\u0642\u064a\u062a CT \u0628\u0648\u0627\u0633\u0637\u0629 \u0645\u064a\u0644\u064a\u0646\u062f \u0648\u0627\u064a \u062f\u064a\u0633\u0627\u064a\u060c \u062f\u0643\u062a\u0648\u0631 \u0641\u064a \u0627\u0644\u0637\u0628\u060c \u0648\u062f\u0631\u062c\u0629 \u0627\u0644\u0645\u0627\u062c\u0633\u062a\u064a\u0631 \u0641\u064a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u0623\u0639\u0645\u0627\u0644. \u0639\u0631\u0636 \u0634\u0641\u0647\u064a \u0645\u0624\u062e\u0631 \u0645\u0646\u0641\u0635\u0644 \u0644\u0640 \u0639\u0644\u0627\u062c \u062c\u064a\u0646\u064a \u0644\u0625\u0639\u0627\u062f\u0629 \u0628\u0631\u0645\u062c\u0629 \u0627\u0644\u062e\u0644\u064a\u0629 \u064a\u064f\u0638\u0647\u0631 \u062a\u062d\u0633\u0646\u064b\u0627 \u0643\u0628\u064a\u0631\u064b\u0627 \u0648\u0645\u0633\u062a\u062f\u0627\u0645\u064b\u0627 \u0641\u064a \u0648\u0638\u064a\u0641\u0629 \u0627\u0644\u0642\u0644\u0628 \u0641\u064a \u0646\u0645\u0648\u0630\u062c \u0641\u0634\u0644 \u0642\u0644\u0628\u064a \u0625\u0633\u0643\u064a\u0645\u064a \u062e\u0646\u0632\u064a\u0631\u064a \u0633\u064a\u064f\u0642\u062f\u0645 \u0641\u064a 9 \u0646\u0648\u0641\u0645\u0628\u0631 2025\u060c 8:00\u20138:10 \u0635 \u0628\u062a\u0648\u0642\u064a\u062a CT \u0628\u0648\u0627\u0633\u0637\u0629 \u0643\u0627\u062b\u064a \u0622\u064a\u0641\u064a.<\/p>\n

\u0633\u062a\u0633\u062a\u0636\u064a\u0641 Tenaya \u0628\u062b\u064b\u0627 \u0645\u0628\u0627\u0634\u0631\u064b\u0627 \u0648\u0645\u0643\u0627\u0644\u0645\u0629 \u0645\u0624\u062a\u0645\u0631\u0627\u062a \u0641\u064a 10 \u0646\u0648\u0641\u0645\u0628\u0631 2025 \u0627\u0644\u0633\u0627\u0639\u0629 8:00 \u0635 \u0628\u062a\u0648\u0642\u064a\u062a \u0634\u0631\u0642 \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0644\u0645\u0646\u0627\u0642\u0634\u0629 \u0628\u064a\u0627\u0646\u0627\u062a MyPEAK-1\u061b \u0648\u0633\u062a\u064f\u0646\u0634\u0631 \u0627\u0644\u0639\u0631\u0648\u0636 \u0627\u0644\u062a\u0642\u062f\u064a\u0645\u064a\u0629 \u0639\u0644\u0649 \u0645\u0648\u0642\u0639 \u0627\u0644\u0634\u0631\u0643\u0629 \u0639\u0644\u0649 \u0627\u0644\u0648\u064a\u0628 \u0628\u0639\u062f \u0643\u0644 \u062c\u0644\u0633\u0629.<\/p>\n

Positive<\/p>\n


\n
\n Interim safety and efficacy reported from MyPEAK-1 dose cohorts 1 and 2
\n
\n Preclinical pig study showed significant, durable cardiac function improvement
\n <\/p>\n

Negative<\/p>\n


\n
\n Clinical results are described as interim and incomplete for final assessment
\n
\n Preclinical pig-model results do not establish efficacy in humans
\n <\/p>\n

<\/p>\n


\n Insights \n <\/p>\n


\n <\/p>\n

Early human safety and efficacy signals from TN-201 are being shared as interim data at AHA; details and metrics are not provided here.<\/p>\n

Tenaya will present interim safety and efficacy results from dose cohorts 1 and 2 of the MyPEAK-1 Phase 1b\/2a study of TN-201 on November 8, 2025. The presentation is an oral late-breaking session led by a Cleveland Clinic investigator, which signals academic engagement and clinical interest.<\/p>\n

Without numerical safety or efficacy figures, the disclosed fact of an interim presentation conveys progress but not outcome quality. Key dependencies are the explicit safety profile, objective efficacy measures, and cohort sizes disclosed in the slides or webcast on November 10, 2025. Watch for exact adverse event rates, functional or biomarker endpoints, and durability across cohorts in the company presentation within one to two weeks.<\/p>\n

Preclinical pig data on direct reprogramming will be presented as late-breaking work; the release does not supply quantitative results.<\/p>\n

Tenaya will present a preclinical study reporting “significant and durable improvement” in cardiac function in a pig ischemic heart failure model at AHA on November 9, 2025. The abstract notes precise delivery via guided intramyocardial injection catheter and names a senior Tenaya researcher as presenter, indicating internal ownership of the data.<\/p>\n

Because the announcement contains no effect sizes, statistical significance values, or histological\/mechanistic detail, the result should be treated as a progress signal rather than definitive proof of translational readiness. Monitor the slide deck and the webcast for numeric cardiac function changes, sample sizes, timing of follow-up, and any safety or off-target findings reported within days after the session.<\/p>\n


\n <\/p>\n


\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 11\/04\/2025 – 05:30 PM
\n
\n <\/p>\n

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results\u00a0from the MyPEAK\u2122-1 Phase 1b\/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy<\/p>\n

Second Late-Breaking Presentation on Sunday to Showcase Results of Cellular Reprogramming Gene Therapy Treatment in Pig Model of Ischemic Heart Failure<\/p>\n

Tenaya Management to Host Webcast Conference Call on Monday, November 10, 2025, to Review MyPEAK-1 Data<\/p>\n

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA<\/a>), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced two late-breaking oral presentations at the American Heart Association (AHA) 2025 Scientific Sessions taking place November 7-10, 2025, in New Orleans, Louisiana.<\/p>\n

The AHA presentation of new TN-201 clinical data will include interim safety and efficacy results from dose cohorts 1 and 2 in the MyPEAK-1 Phase 1b\/2a clinical trial of TN-201. TN-201 is being developed for the potential treatment of myosin-binding protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C).<\/p>\n

Details of the TN-201 clinical data presentation are as follows:<\/p>\n

Abstract Title: TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib\/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated Hypertrophic Cardiomyopathy
Session Type: Late-Breaking Science: Main Event (Oral Presentation)
Session Title: Forgotten No More: The Current Belle of the Ball? Breakthrough Evolutions in Hypertrophic Cardiomyopathy
Presenting Author: Milind Y Desai, M.D., MBA, director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic and vice chair of Cleveland Clinic\u2019s Heart, Vascular & Thoracic Institute
Presentation Date & Time: Saturday, November 8, 2025, from 10:25 am \u2013 10:35 am CT<\/p>\n

Tenaya will also present results from a preclinical study of its cellular reprogramming treatment in a pig model of ischemic heart failure. The goal of reprogramming gene therapy is to improve heart function following ischemic injury through cardiac cell regeneration. Details for this late-breaking presentation are below:<\/p>\n

Abstract Title: First Demonstration of Significant and Durable Improvement of Cardiac Function in Pig Model of Ischemic Heart Failure with Direct Reprogramming Delivered Precisely to Infarct Border via Guided Intramyocardial Injection Catheter
Session Type: Late-Breaking Basic Science (Oral Presentation)
Session Title: Next-Generation Therapies for Ischemic Heart Repair: From Cells to Imaging
Presenting Author: Kathy Ivey, Senior Vice President of Research, Tenaya Therapeutics
Presentation Date & Time: Sunday, November 9, 2025, from 8:00 am \u2013 8:10 am CT<\/p>\n

Copies of the presentations at AHA Scientific Sessions 2025 will be available in the \u201cOur Science\u201d and \u201cInvestors\u201d sections of the company\u2019s website following each late-breaking session.<\/p>\n

Conference Call and Webcast
Tenaya management will host a conference call on Monday, November 10, 2025, at 8:00 a.m. ET\/5:00 a.m. PT to discuss the TN-201 data being presented at the upcoming American Heart Association Scientific Sessions 2025.\u00a0 Investors and analysts are invited to participate by joining the webcast<\/a>. The webcast can be accessed from the investor section of the Tenaya website at www.tenayathera.com.<\/p>\n

About\u00a0Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya\u2019s pipeline includes clinical-stage candidates TN-201, a gene therapy for\u00a0MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for\u00a0PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio\/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit\u00a0www.tenayatherapeutics.com<\/a>.<\/p>\n

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com<\/a><\/p>\n

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com<\/a><\/p>\n

Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com<\/a><\/p>\n

\"\"
\"\"
\n
\n
\n
\n
\n
\n
\n
\n
\n <\/p>\n


\n FAQ \n <\/p>\n


\n
\n <\/p>\n

What TN-201 MyPEAK-1 data will Tenaya (TNYA) present at AHA 2025?<\/p>\n


\n Tenaya will present interim safety and efficacy results from dose cohorts 1 and 2 of the MyPEAK-1 Phase 1b\/2a study. \n <\/p>\n


\n <\/p>\n

When and who will present Tenaya’s TN-201 MyPEAK-1 results at AHA 2025?<\/p>\n


\n The TN-201 oral presentation is on Nov 8, 2025, 10:25\u201310:35 am CT, presented by Milind Y Desai, M.D., MBA. \n <\/p>\n


\n <\/p>\n

What preclinical data will Tenaya (TNYA) share at AHA 2025 and when?<\/p>\n


\n On Nov 9, 2025, 8:00\u20138:10 am CT Tenaya will present pig-model results showing significant and durable improvement in cardiac function after direct reprogramming therapy. \n <\/p>\n


\n <\/p>\n

How can investors access Tenaya’s AHA presentations and webcast for TNYA?<\/p>\n


\n Presentations will be posted in the company’s Our Science and Investors pages; the webcast is scheduled for Nov 10, 2025 at 8:00 am ET via Tenaya’s investor website. \n <\/p>\n


\n <\/p>\n

Do the MyPEAK-1 TN-201 results represent final clinical outcomes for TNYA?<\/p>\n


\n No; the company describes the data as interim from early dose cohorts, not final trial outcomes. \n <\/p>\n


\n <\/p>\n

Does the pig-model reprogramming result prove TN-201 effectiveness in humans?<\/p>\n


\n No; the presentation reports preclinical animal results, which do not establish human efficacy. \n <\/p>\n


\n
\n
\n
\n
\n <\/p>\n","protected":false},"excerpt":{"rendered":" Tenaya Therapeutics (NASDAQ: TNYA) announced two late-breaking oral presentations at…\n","protected":false},"author":2,"featured_media":271784,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[29779,4,450,145335,145339,36244,141566,451,145337,145333,145332,145331,3,145334,145336,145328,145330,145329,452,453,145338],"class_list":["post-271783","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-american-heart-association","tag-breaking-news","tag-breakingnews","tag-cellular-reprogramming","tag-clinical-stage-biotechnology","tag-conference-call","tag-hcm","tag-headlines","tag-ischemic-heart-failure","tag-late-breaking-presentation","tag-mybpc3-associated-hypertrophic-cardiomyopathy","tag-mypeak-1","tag-news","tag-phase-1b-2a","tag-pig-model","tag-tenaya-therapeutics","tag-tn-201","tag-tnya","tag-top-stories","tag-topstories","tag-webcast"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/271783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=271783"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/271783\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/271784"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=271783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=271783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=271783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}